Table 4. KEGG pathway enrichment of dysregulated mRNAs in STAD.
| Items | Items_Details | FDR | Genes |
|---|---|---|---|
| hsa04971 | Gastric acid secretion | 1.98E-05 | SLC9A4, CALML3, CFTR, ADCY2, KCNE2, KCNJ15, SLC26A7, KCNQ1, SSTR2 |
| hsa04610 | Complement and coagulation cascades | 5.21E-05 | F10, F2R, SERPINA1, C5, C8A, F5, CR2, C7 |
| hsa04972 | Pancreatic secretion | 9.20E-05 | CFTR, CLCA4, ADCY2, CLCA2, KCNQ1, RYR2, TRPC1, CCKAR, PLA2G4E |
| hsa04640 | Hematopoietic cell lineage | 0.001457 | KIT, ITGA2, CSF3R, CSF3, CR2, MME, IL11RA |
| hsa05322 | Systemic lupus erythematosus | 0.001691 | HIST1H2BM, C5, C8A, HIST1H2AE, HIST1H2BE, FCGR3A, C7 |
| hsa05020 | Prion diseases | 0.001992 | C5, C8A, C7 |
| hsa00480 | Glutathione metabolism | 0.002214 | IDH2, GSTP1, RRM2, PGD, GSTA4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 0.002473 | AKR1C4, CYP2B6, DHDH, GSTP1, GSTA4, ADH1B |
| hsa04060 | Cytokine-cytokine receptor interaction | 0.002843 | KIT, CXCL9, CXCL5, CXCL1, CCR8, LIFR, EDA, TNFSF15, CSF3R, CSF3, IL11RA |
| hsa00590 | Arachidonic acid metabolism | 0.002877 | CYP2B6, ALOX12B, PTGIS, PLA2G4E, PTGS2 |
| hsa04640 | Hematopoietic cell lineage | 0.002996 | KIT, CSF3R, CSF3, IL11RA |
| hsa00010 | Glycolysis / Gluconeogenesis | 0.00308 | FBP2, ALDOB, HKDC1 |
| hsa00051 | Fructose and mannose metabolism | 0.00308 | FBP2, ALDOB, HKDC1 |
| hsa04970 | Salivary secretion | 0.003109 | CALML3, ADCY2, MUC5B, DMBT1, AQP5, CST1 |
| hsa04978 | Mineral absorption | 0.003124 | MT2A, SLC26A9, HEPH, MT1E, SLC9A3 |
| hsa04020 | Calcium signaling pathway | 0.003165 | ADCY2, RYR2, TRPC1, CCKAR |
| hsa05200 | Pathways in cancer | 0.003449 | HIF1A, KIT, LAMA2, ITGA2, CSF3R, FGF13, GSTP1, WNT5A, BRCA2, LAMC2, PTGS2, MMP1 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 0.007626 | RYR2, LAMA2, ITGA2, CACNA2D3, CDH2 |
| hsa04630 | Jak-STAT signaling pathway | 0.007986 | CSF3R, CSF3, IL11RA |
| hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate | 0.00833 | XYLT2, B3GAT1, CHST3 |
STAD: stomach adenocarcinoma; FDR: false discovery rate.